



## Observational study of mental health in asthmatic women during the prenatal and postnatal periods

Olivia M. Whalen, Linda E. Campbell, Vanessa E. Murphy, Alison E. Lane, Peter G. Gibson, Joerg Mattes, Adam Collison, Carly A. Mallise, Alix Woolard & Frini Karayanidis

To cite this article: Olivia M. Whalen, Linda E. Campbell, Vanessa E. Murphy, Alison E. Lane, Peter G. Gibson, Joerg Mattes, Adam Collison, Carly A. Mallise, Alix Woolard & Frini Karayanidis (2019): Observational study of mental health in asthmatic women during the prenatal and postnatal periods, Journal of Asthma, DOI: [10.1080/02770903.2019.1621888](https://doi.org/10.1080/02770903.2019.1621888)

To link to this article: <https://doi.org/10.1080/02770903.2019.1621888>



Published online: 31 May 2019.



Submit your article to this journal [↗](#)



Article views: 8



View Crossmark data [↗](#)



## Observational study of mental health in asthmatic women during the prenatal and postnatal periods

Olivia M. Whalen, BPsych (Hons)<sup>a,b</sup>, Linda E. Campbell, BSc (Hons), MCLinPsychol, PhD<sup>a,b</sup> ,  
Vanessa E. Murphy, BMedChem(Hons), PhD<sup>b,c,d</sup> , Alison E. Lane, PhD, OTR/L<sup>b,e</sup> ,  
Peter G. Gibson, MBBS, FRACP<sup>c,d,f,g</sup> , Joerg Mattes, MD, PhD<sup>b,c,d,h</sup> , Adam Collison, PhD<sup>b,c,d</sup>,  
Carly A. Mallise, BPsych (Hons)<sup>a,b</sup>, Alix Woolard, BPsych (Hons)<sup>a,b</sup>, and Frini Karayanidis, PhD<sup>a,i</sup> 

<sup>a</sup>School of Psychology, University of Newcastle, Callaghan, NSW, Australia; <sup>b</sup>Priority Research Centre GrowUpWell, University of Newcastle, Callaghan, NSW, Australia; <sup>c</sup>Hunter Medical Research Institute, Newcastle, NSW, Australia; <sup>d</sup>School of Medicine and Public Health, University of Newcastle, Callaghan, NSW, Australia; <sup>e</sup>School of Health Sciences, University of Newcastle, Callaghan, NSW, Australia; <sup>f</sup>Department of Respiratory and Sleep Medicine, John Hunter Hospital, Newcastle, NSW, Australia; <sup>g</sup>Priority Research Centre for Healthy Lungs, University of Newcastle, Newcastle, NSW, Australia; <sup>h</sup>Department of Paediatric Respiratory and Sleep Medicine, John Hunter Children's Hospital, Newcastle, NSW, Australia; <sup>i</sup>Priority Research Centre for Stroke and Brain Injury, University of Newcastle, Callaghan, NSW, Australia

### ABSTRACT

**Objective:** We aimed to examine the prevalence and severity of psychological distress of women with asthma in both the prenatal and postnatal periods, and to determine whether asthmatic women with and without mental health problems differ in self-management, medications knowledge, and asthma symptoms.

**Methods:** We assessed spirometry performance and asthma symptoms in 120 women (mean age 29.8 years) before 23 weeks gestation, as part of the Breathing for Life Trial (Trial ID: ACTRN12613000202763). Prenatal depression data was obtained from medical records. At 6 weeks postpartum, we assessed general health, self-reported asthma control, depression symptoms (with the Edinburgh Postnatal Depression Scale) and adaptive functioning (with the Achenbach System of Empirically Based Assessment scales).

**Results:** Twenty percent of our sample reported having a current mental health diagnosis, 14% reported currently receiving mental health care, while 47% reported having received mental health care in the past (and may/may not have received a diagnosis). The sample scored high on the Aggressive Behavior, Avoidant Personality, and Attention Deficit/Hyperactivity scales. Poorer self-reported postnatal asthma control was strongly correlated with elevated somatic complaints, externalizing problems, antisocial personality problems, and greater withdrawal. Prenatal spirometry or asthma severity and control were largely not associated with measures of psychopathology.

**Conclusions:** These findings indicate that pregnant women with asthma frequently report issues with psychopathology during the prenatal and postnatal periods, and that the subjective perception of asthma control may be more related to psychopathology than objective asthma measures. However, due to sample bias, these findings are likely to be understated.

### ARTICLE HISTORY

Received 22 January 2019  
Revised 18 March 2019  
Accepted 16 May 2019

### KEYWORDS

Prenatal depression;  
postnatal depression;  
psychopathology; adaptive  
functioning; asthma during  
pregnancy; asthma severity;  
asthma control

## Introduction

Asthma is one of the most common medical conditions to affect women during pregnancy (1). In Australia, ~12% of pregnant women experience symptoms of asthma (2). The global prevalence of asthma during pregnancy ranges between 4% and 12% (3–5). Pregnant women with asthma are at risk of experiencing higher frequency and severity of asthma exacerbations, especially amongst more severe asthma cases (6). Furthermore, asthma and asthma exacerbations

during pregnancy are linked to increased risk of adverse perinatal outcomes, including pre-eclampsia, preterm birth, low infant birth weight, and small for gestational age, compared to non-asthmatic women (7–10). It is important, therefore, to minimize the occurrence of asthma exacerbations through active asthma management (7,11,12). However, adherence to asthma control plans may be affected by mental health, an issue particularly salient for asthmatic women in the perinatal period (13).

**CONTACT** Frini Karayanidis  [frini.karayanidis@newcastle.edu.au](mailto:frini.karayanidis@newcastle.edu.au)  School of Psychology, University of Newcastle, Callaghan, 2308 NSW, Australia. The Breathing for Life Trial is registered with the Australian New Zealand Clinical Trials Registry (Trial ID: ACTRN12613000202763).

© 2019 Taylor & Francis Group, LLC

The risk of depression and anxiety in women increases during prenatal and postpartum periods. A recent Australian retrospective cohort study reported rates of depression antenatally at 6.2%, and postnatally at 3.3% (14). Other Australian studies have reported antenatal depression rates of 7% (15), 17% (16), and almost 30% (17), whereas rates of postnatal depression range from 6% to 12% (16,18). In Australia, depression affects ~5.1% of women in any given 12 month period (19). Worldwide, estimates of postpartum depression are 6.5%–12.9% (20–22).

Many studies report that poor maternal mental health perinatally can have long-term negative impacts on the infant's development. Maternal antenatal depression is associated with reduced infant growth rate and increased risk of diarrhea (23). Postnatal depression has been associated with impaired mother-child interactions (24), less efficient parenting (25) and less attention to infant safety (26), which in turn can lead to behavioral, cognitive, socio-emotional, and health problems in the infant (27). Importantly, a recent study indicated that depressive symptoms experienced by mothers during the first 6–7 years of their child's life are associated with increased incidence of childhood asthma, even when controlling for a history of maternal asthma (28). Taken together, these findings clearly indicate the clinical importance of understanding the nature and prevalence of perinatal psychopathology in asthmatic mothers.

Poor mental health has been associated with asthma (29). Adults with asthma have a higher risk of depression and anxiety compared to the general population (30). Asthmatic individuals who experience psychological distress often have less controlled asthma control and higher rates of hospitalization (31–35). However, the association between asthma severity and anxiety or depression, is not robust. While one study reported that asthma severity was positively correlated with depressive problems (32), another found no difference in the incidence of reported depression between those with mild or severe asthma (36). It has been suggested that depressive symptoms such as reduced motivation, energy, and cognitive functioning may interfere with self-management behaviors, leading to poorer asthma outcomes (31,37). A negatively reinforcing cycle may develop: depression may increase treatment non-adherence, which can exacerbate asthma symptoms, and this, in turn, may increase depressive symptom severity (38,39).

Conversely, the associations between asthma and poor mental health may reflect the complex, bidirectional interactions between the immune and nervous systems, particularly through the signaling of G protein-coupled cell surface receptors, receptor tyrosine

kinases, cytokines, growth factors, and neuropeptides during inflammation (40). Thoren and Petermann (41) noted that, in individuals with comorbid asthma and anxiety, a fear of asthma symptoms would be expected to increase motivation to effectively manage and control asthma symptoms. However, they argue that intense asthma-related anxiety may trigger asthma symptoms, which may compromise engagement in self-management behaviors and lead to reduced quality of life. The higher mortality rates amongst asthmatic adults with a comorbid diagnosis of depression (42) support this notion.

There is a paucity of research on perinatal mental health amongst women with asthma. Recent studies report that the risk for depression and anxiety in pregnant women ranges from 6.1% (43), to 28% (44) to 45% (13). Other studies suggest that the risk of depression during pregnancy may increase with greater asthma severity and associated exacerbations (45), and that anxiety may significantly increase the odds of subsequent exacerbations during pregnancy (46). This is consistent with the findings of a recent study showing that uncontrolled asthma was more common in asthmatic pregnant women who also experienced anxiety and depression (13).

On the other hand, amongst asthmatic adults, the use of oral corticosteroids (OCS) to treat asthma exacerbations has been associated with depressive symptoms (47), and depression was associated with longer duration of OCS use (48) as well as higher doses of ICS (e.g. (49)).

In summary, there is some evidence that pregnant women with asthma have heightened risk of depression and anxiety, which in turn, may impact asthma exacerbations during pregnancy. However, the mental health characteristics of asthmatic women in the postpartum period, which is associated with higher risk of depression and anxiety, have not been well-characterised. The current study has three primary aims: (1) to examine the prevalence and severity of psychological distress of women with asthma in both the prenatal and postnatal periods, (2) to examine whether asthmatic women with and without mental health problems differ in self-management, medications knowledge, and asthma symptoms, and (3) to examine whether subjective and objective measures of asthma severity are related to psychological distress.

## Methods

### Participants

Pregnant women at 12–22 weeks gestation were recruited from the greater Newcastle, Australia area to the current

study as part of the Breathing for Life Trial (BLT), a large randomized clinical trial (RCT) examining the effects of a novel asthma management strategy for pregnant women (50). The BLT is registered with the Australian New Zealand Clinical Trials Registry (Trial ID: ACTRN12613000202763). Participants were included if they were aged over 18 years, had an asthma diagnosis from a physician, had symptoms of and/or treatment for asthma in the last 12 months, and reported no additional lung disease, no drug or alcohol dependence, and no requirement for OCS use for >14 days in the past 3 months. Participants were randomized to either a control or intervention group, in a 1:1 ratio with block sizes of four or six. From June 2015 through to September 2017, 259 BLT participants were invited into the current study, of which 155 were randomized to the active intervention arm of the RCT. As this RCT is ongoing, data regarding intervention effects is not yet available. A total of 120 participants (60 from the intervention arm and 60 from the treat-as-usual arm) consented to participate in the current study (mean age =  $29.8 \pm 5.4$  years). These participants had been recruited into the BLT study between November 2014 and March 2017.

## Procedure

Consenting participants completed prenatal asthma and mental health measures (described below) and at 6 weeks postpartum (range 4–8 weeks) participants were asked to complete further ratings of mental health symptoms along with sociodemographic and medical history questionnaires. Information collected included maternal country of birth, age, marital status, current breastfeeding, and/or formula feeding status, primiparity, medical conditions in addition to asthma, personal, and family history of psychopathology (current and past presence of a mental health condition), annual household income (as an marker of socioeconomic status; SES), medical history, and maternal education level. Women who reported experiencing high levels of psychological distress were offered the services of a clinical psychologist.

Participants were reimbursed \$20 for expenses. This study was approved by the Hunter New England Human Research Committee and the University of Newcastle Human Ethics Research Committee (HREC approval number 15/05/20/4.05).

## Measures

### Asthma measures

Prenatal data, including body mass index (BMI, kg/m<sup>2</sup>), smoking status, weeks gestation, age at asthma

diagnosis, as well as hospital admissions, emergency department visits, and OCS use for asthma in the previous year were collected before participants reached 23 weeks gestation. Forced expiratory volume in 1 s (FEV<sub>1</sub>) and forced vital capacity (FVC) were measured prenatally using spirometry. Age-adjusted and height-adjusted % predicted FEV<sub>1</sub> and FVC were calculated in line with the 2012 Global Lung Function equations [51]. Adherence and self-management skills were also assessed prenatally. Adherence to inhaled corticosteroids was assessed by asking participants “It can be difficult to remember all of your medicines when things get busy. How many times in the last week have you missed a dose of your preventer?” Participants who had missed more than 20% of their medication doses were considered to be non-adherent. Knowledge about preventer and reliever medication was determined by asking women direct questions about how each medication worked and when they were to use each type, and responses were scored by trained nurses/midwives. Participants were also asked whether they had a written action plan and to demonstrate correct use of their inhaler, in accordance with the technique described in Murphy, Gibson, Talbot, Kessel, and Clifton (52). At 6 weeks postpartum, participants completed the Juniper Asthma Control Questionnaire (ACQ) (53) and women scoring above 1.5 were considered to have uncontrolled asthma (54). The list of measures completed by women who consented to participate in this study (participants) and women who only participated in the larger BLT project (non-participants) is shown in Table 1.

### Asthma severity and control classifications

Prenatally, participants were classified as having mild, moderate, or severe asthma using criteria from the Global Initiative for Asthma guidelines (GINA) (55). In brief, we used treatment step as a surrogate measure of ‘asthma severity’. Women using step 1 (reliever alone) or step 2 (low dose inhaled corticosteroid; ICS) therapy were considered to have mild asthma. Women using step 3 (low dose ICS/long-acting beta agonist; LABA or medium/high dose ICS) therapy were considered to have moderate asthma. Women using step 4 (medium/high dose ICS/LABA) therapy were considered to have severe asthma.

‘Asthma control’ was classified as well controlled, partly controlled or uncontrolled according to an adaptation of the GINA criteria. Asthma was well controlled if there were none of the following symptoms in the previous week: night waking, activity

**Table 1.** Prenatal measures for participants and non-participants of the current study.

|                                                                     | Participants |                      | Non-participants |                      | $p < .05$<br>$p = .013^{**}$ | $p < .05$ after FDR<br>correction<br>$p = .091$ |
|---------------------------------------------------------------------|--------------|----------------------|------------------|----------------------|------------------------------|-------------------------------------------------|
|                                                                     | <i>N</i>     | <i>M</i> ( $\pm$ SD) | <i>N</i>         | <i>M</i> ( $\pm$ SD) |                              |                                                 |
| Prenatal EPDS                                                       | 102          | 5.26 ( $\pm$ 4.00)   | 118              | 6.76 ( $\pm$ 4.72)   |                              |                                                 |
| 0–9 (Low risk)                                                      | 92 (91%)     |                      | 85 (70%)         |                      | $p = .002^{**}$              | $p = .028^*$                                    |
| 10–12 (Medium risk)                                                 | 3 (3.4%)     |                      | 17 (16%)         |                      |                              |                                                 |
| 13–30 (High risk)                                                   | 7 (5.6%)     |                      | 16 (14%)         |                      |                              |                                                 |
| BMI                                                                 | 119          | 30.74 ( $\pm$ 7.91)  | 139              | 29.83 ( $\pm$ 8.54)  | $p = .337$                   | $p = .786$                                      |
| Age                                                                 | 119          | 29.30 ( $\pm$ 5.29)  | 142              | 29.44 ( $\pm$ 5.84)  | $p = .845$                   | $p = .845$                                      |
| Asthma control questionnaire <sup>a</sup>                           | 60           | 1.46 ( $\pm$ 1.00)   | 67               | 1.63 ( $\pm$ .97)    | $p = .344$                   | $p = .602$                                      |
| FEV <sub>1</sub> /FVC %                                             | 107          | 81.97 ( $\pm$ 7.51)  | 124              | 81.37 ( $\pm$ 7.14)  | $p = .534$                   | $p = .748$                                      |
| FEV <sub>1</sub> %                                                  | 111          | 88.21 ( $\pm$ 12.38) | 124              | 89.09 ( $\pm$ 12.32) | $p = .588$                   | $p = .686$                                      |
| FVC %                                                               | 108          | 90.84 ( $\pm$ 10.98) | 124              | 92.47 ( $\pm$ 10.43) | $p = .248$                   | $p = .868$                                      |
| Smoking status                                                      | <i>N</i>     | (%)                  | <i>N</i>         | (%)                  |                              |                                                 |
| Current                                                             | 13           | 11%                  | 36               | 26%                  | $p = .018^*$                 | $p = .084$                                      |
| Ex                                                                  | 31           | 26%                  | 43               | 30%                  |                              |                                                 |
| Never                                                               | 74           | 63%                  | 61               | 44%                  |                              |                                                 |
| Adherent <sup>b</sup> (missed <20% of ICS dose)                     | 27           | 60%                  | 27               | 53%                  | $p = .465$                   | $p = .814$                                      |
| History (times in the past year)                                    |              |                      |                  |                      |                              |                                                 |
| Emergency visits                                                    |              |                      |                  |                      | $p = .735$                   | $p = .735$                                      |
| 0                                                                   | 103          | 87%                  | 120              | 85%                  |                              |                                                 |
| 1 or more                                                           | 16           | 13%                  | 22               | 15%                  |                              |                                                 |
| Hospital visits                                                     |              |                      |                  |                      | $p = .539$                   | $p = .686$                                      |
| 0                                                                   | 112          | 93%                  | 134              | 93%                  |                              |                                                 |
| 1 or more                                                           | 7            | 6%                   | 8                | 6%                   |                              |                                                 |
| Missing                                                             | 1            | 1%                   | 2                | 1%                   |                              |                                                 |
| Medication type                                                     |              |                      |                  |                      | $p = .488$                   | $p = .759$                                      |
| ICS                                                                 | 11           | 9%                   | 18               | 28%                  |                              |                                                 |
| ICS/LABA                                                            | 34           | 29%                  | 33               | 51%                  |                              |                                                 |
| Other                                                               | 4            | 3%                   | 6                | 9%                   |                              |                                                 |
| SABA                                                                | 69           | 59%                  | 8                | 12%                  |                              |                                                 |
| Correct Knowledge                                                   |              |                      |                  |                      |                              |                                                 |
| Action plan                                                         | 12           | 48%                  | 4                | 16%                  | $p = .013^*$                 | $p = .091$                                      |
| Preventer                                                           | 2            | 8%                   | 6                | 24%                  | $p = .076$                   | $p = .266$                                      |
| Reliever                                                            | 11           | 44%                  | 15               | 60%                  | $p = .662$                   | $p = .713$                                      |
| Technique                                                           |              |                      |                  |                      |                              |                                                 |
| Preventer (Pressurised metered dose inhaler)                        |              |                      |                  |                      | $p = .103$                   | $p = .288$                                      |
| Optimal                                                             | 32           | 27%                  | 22               | 16%                  |                              |                                                 |
| Adequate                                                            | 7            | 6%                   | 10               | 7%                   |                              |                                                 |
| Inadequate                                                          | 66           | 55%                  | 81               | 58%                  |                              |                                                 |
| Missing                                                             | 14           | 12%                  | 27               | 19%                  |                              |                                                 |
| Turbuhaler                                                          |              |                      |                  |                      | $p = .630$                   | $p = .735$                                      |
| Optimal                                                             | 20           | 22%                  | 26               | 18%                  |                              |                                                 |
| Adequate                                                            | 3            | 3%                   | 4                | 3%                   |                              |                                                 |
| Inadequate                                                          | 1            | 1%                   | 5                | 4%                   |                              |                                                 |
| Missing                                                             | 68           | 74%                  | 104              | 75%                  |                              |                                                 |
| Activity limitation (days/week)                                     |              |                      |                  |                      |                              |                                                 |
| 0                                                                   | 78           | 65%                  | 92               | 68%                  | $p = .510$                   | $p = .714$                                      |
| 1–5                                                                 | 27           | 23%                  | 24               | 18%                  |                              |                                                 |
| 6–7                                                                 | 14           | 12%                  | 20               | 14%                  |                              |                                                 |
| Mornings                                                            |              |                      |                  |                      |                              |                                                 |
| 0                                                                   | 48           | 40%                  | 51               | 40%                  | $p = .332$                   | $p = .664$                                      |
| 1–5                                                                 | 45           | 38%                  | 38               | 29%                  |                              |                                                 |
| 6–7                                                                 | 26           | 22%                  | 40               | 31%                  |                              |                                                 |
| Nights                                                              |              |                      |                  |                      |                              |                                                 |
| 0                                                                   | 38           | 32%                  | 34               | 29%                  | $p = .112$                   | $p = .261$                                      |
| 1–5                                                                 | 54           | 45%                  | 44               | 37%                  |                              |                                                 |
| 6–7                                                                 | 27           | 23%                  | 41               | 34%                  |                              |                                                 |
| GINA Asthma severity and control classifications (during pregnancy) |              |                      |                  |                      |                              |                                                 |
| Asthma severity                                                     | <i>N</i>     | (%)                  |                  |                      |                              |                                                 |
| Mild                                                                | 81           | (68.1)               |                  |                      |                              |                                                 |
| Moderate                                                            | 10           | (8.4)                |                  |                      |                              |                                                 |
| Severe                                                              | 28           | (23.5)               |                  |                      |                              |                                                 |
| Asthma control                                                      |              |                      |                  |                      |                              |                                                 |
| Uncontrolled                                                        | 60           | (50.4)               |                  |                      |                              |                                                 |
| Partly controlled                                                   | 37           | (31.1)               |                  |                      |                              |                                                 |
| Well controlled                                                     | 22           | (18.5)               |                  |                      |                              |                                                 |
| Asthma severity and control                                         |              |                      |                  |                      |                              |                                                 |
| Mild uncontrolled                                                   | 36           | (30.3)               |                  |                      |                              |                                                 |

(Continued)

Table 1. Continued.

|                                       | Participants |                      | Non-participants |                      | $p < .05$<br>$p = .013^{**}$ | $p < .05$ after FDR<br>correction<br>$p = .091$ |
|---------------------------------------|--------------|----------------------|------------------|----------------------|------------------------------|-------------------------------------------------|
|                                       | <i>N</i>     | <i>M</i> ( $\pm$ SD) | <i>N</i>         | <i>M</i> ( $\pm$ SD) |                              |                                                 |
| Prenatal EPDS                         | 102          | 5.26 ( $\pm$ 4.00)   | 118              | 6.76 ( $\pm$ 4.72)   |                              |                                                 |
| Mild partly controlled and controlled | 45           | (37.8)               |                  |                      |                              |                                                 |
| Moderate-severe uncontrolled          | 24           | (20.2)               |                  |                      |                              |                                                 |
| Moderate-severe controlled            | 14           | (11.8)               |                  |                      |                              |                                                 |

For all of the chi-squared analyses, some cells had expected counts  $<5$  so an exact significance test was selected for Pearson's chi square.  $p$  values are bolded if significant after FDR correction.

Abbreviations: FDR = False discovery rate;  $N$  = sample size;  $M$  = sample mean; SD = sample standard deviation; % = percent;  $p = p$  values; FEV<sub>1</sub>/FVC % = Ratio of forced expiratory volume in 1 s and forced vital capacity percentage; FEV<sub>1</sub>% = Forced expiratory volume in 1 s percentage; FVC % = Forced vital capacity percentage; ICS = Inhaled corticosteroid; LABA = Long acting beta agonist; SABA = Slow acting beta agonist.

\* $p < .05$ .

\*\* $p < .01$ .

<sup>a</sup>Intervention participants only.

<sup>b</sup>Calculated for participants taking ICS/ICS LABA medications only.

limitation, daytime symptoms  $>2$  times per week, or reliever use  $>2$  times per week. If 1–2 of these symptoms were present, asthma was considered to be partly controlled, and if 3–4 symptoms were present, was considered to be uncontrolled.

### Mental health measures

Participants completed the Edinburgh Postnatal Depression Scale (EPDS) (56) at their first antenatal appointment (second trimester of pregnancy) as part of routine antenatal care. At the postpartum visit, participants completed both the EPDS and the Adult Self Report (ASR) from the Achenbach System of Empirically Based Assessment (ASEBA) (57).

The EPDS is a brief, 10-item self-report scale that screens for postpartum depression. Women are asked to respond in a way that best describes how they have felt in the past week. Apart from one sleep-related item, the EPDS excludes somatic complaints such as fatigue and appetite variations that are typical experiences during the prenatal and postnatal periods. Scores  $\geq 10$  are recommended for referral for diagnostic evaluation of postpartum depression. The EPDS has been validated worldwide and demonstrates high test-retest reliability and internal consistency (56,58–61). It has also been validated for prenatal depression (62).

The ASR is a standardized self-report questionnaire designed for adults aged 18–59 years. The ASR assesses adaptive functioning across a range of domains (i.e., friends, spouse/partner, family, job; education, personal strengths). It generates age and gender normed T-scores across two composite scales (externalizing/internalizing and total problems) and syndrome scales (Anxious/Depressed, Withdrawn, Somatic Complaints, Thought Problems, Attention Problems, Aggressive Behavior, Rule-breaking Behavior, and Intrusive problems). It also produces

scores for Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) (63) oriented scales: depressive, anxiety, somatic, avoidant personality, attention deficit/hyperactivity, and antisocial personality problems. Scores between the 93rd and 97th percentile are considered borderline clinical, and above the 97th percentile are in the clinical range, both signaling the need for further assessment and diagnosis.

### Analysis

Data were analyzed using the Statistical Package for the Social Sciences software for Windows, with level of significance set to  $\alpha = .05$ . To investigate sample bias, demographic, mental health, and asthma data were compared between participants and non-participants. Total scores, percentile scores, and T-scores for DSM-5 oriented scales and syndrome scales of the ASR were derived and categorized in the normal, borderline, or clinical range for each participant. EPDS scoring uses clinical brackets: 0–9 is considered low risk, 10–12 is medium risk, and 13–30 is high risk. Scores from the EPDS and ASR were used to characterize the nature of psychological distress. We used multidimensional  $\chi^2$  analyses, and phi ( $\phi$ ) to measure the association between variables (64). To avoid inflation of type 1 error rate as a result of multiple comparisons, we used false discovery rate (FDR) corrected  $p$  values. FDR is a well-validated way of controlling for multiple comparisons and is less conservative than other Bonferroni-type corrections (65). As many prior studies do not correct for multiple comparisons, we report both uncorrected and FDR-corrected  $p$  values for comparability. Further associations between asthma and psychopathology were determined by computing odds ratios for the association between high ASR scores in this sample of asthmatic women, as compared to normative ASR data. Given that prior

work has found associations between OCS use and depression, we compared total scores on the EPDS and relevant ASR scales between participants who used ICS and those that did not. Multiple regression was used to determine whether mental health explained any variance in GINA control or severity classifications. Specifically, total scores from the DSM-5 oriented scales and syndrome scales of the ASR, prenatal and postnatal EPDS total scores, self-reported presence of mental illness diagnosis (binary yes/no), current psychiatric care (yes/no), past psychiatric care (yes/no), maternal age at the time of their infant's birth, and breastfeeding status were all entered into the model as predictors.

## Results

### Sampling bias

First, we examined whether there were any systematic differences between the 120 participants and 139 non-participants from the larger BLT study. The primary reasons for nonparticipation included: loss to follow-up, too busy, not interested, or they did not attend their BLT appointment. Descriptive measures of mental health and asthma status for participants and non-participants are presented in Table 1. Participants did not significantly differ from non-participants in age, BMI, or any asthma-related measures, with the exception that participants had greater knowledge of their action plan (which was non-significant after FDR correction). Non-participants had higher rates of current smoking, but this did not remain significant after FDR correction. Information on parity, SES and GINA asthma severity, and control classifications was not available for non-participants.

The groups also differed in prenatal mental health status. Prenatal EPDS scores were lower (less mental health risk) in participants than non-participants ( $t(218) = 2.52, p = .013$ ) but the effect was not significant after FDR correction ( $p = .091$ ). A significantly greater percentage of non-participants than participants scored in the medium and high-risk categories, ( $\chi^2(2, N = 220) = 12.50, p = .002$  FDR-corrected:  $p = .028$ ). The strength of the association between EPDS category and group was moderate ( $\phi = 0.238$ ) and participation status accounted for 5.66% of the variance in prenatal depression scores.

### The current sample

Sociodemographic characteristics of participating women were obtained at 6 weeks postpartum. The

majority were born in Australia (95%), Caucasian (83%), well educated (81% completed at least the final year of high school), primiparous (52%), in a relationship (93%), and represented a diverse range of socioeconomic status (52% reported an annual household income over \$80 001 and 19% under \$37 000). Of the infants, 53% were male and 49% were exclusively breastfed. Asthma status was assessed prenatally. In terms of asthma status, 35% of participants were using ICS or ICS/LABA (median dose 500  $\mu$ g), 9% were current smokers, 12% had at least 1 emergency hospital visit in the last year for their asthma, 22.5% were able to demonstrate optimal technique for their inhaler, and 22.5% were adherent to their asthma medication.

### Mental health results

Postnatal EPDS scores, self-reported mental illness diagnoses, psychotropic medications, past and current mental health care, and alcohol and drug use are reported in Table 2. The percentage of participants scoring in the medium-high categories of the EPDS (indicating that they should be referred for evaluation for perinatal depression) rose from 9% prenatally ( $n = 102$ ; Table 1) to 15.5% postnatally ( $n = 110$ ; Table 2). Total scores for prenatal and postnatal depression did not significantly differ ( $t = -0.691, p = .491$ ). However, there were significant differences in the risk category proportions between prenatal and postnatal depression scores  $\chi^2(4, N = 92) = 16.42, p = .003$ . Twenty percent of the sample reported a mental health diagnosis, with 14% currently receiving mental health care, and 47% of participants having received mental health care in the past (but did not necessarily receive a diagnosis of a mental health condition; Table 2). Participants had low rates of current alcohol and drug use, with 73% reporting that they rarely or never drank alcohol, and 59% reporting that they have never used non-prescription drugs (Table 2).

Scores from the internalizing and externalizing problem scales, syndrome scales, and the DSM-5 oriented subscales, of the ASR are presented in Table 3. On most subscales, the percentage of women scoring in the borderline or clinical range (above the 93rd percentile) was less than the expected 7%. However, somewhat higher than expected percentages were found for the Aggressive Behavior Syndrome scale (9.5%), as well as the Avoidant Personality and Attention Deficit Hyperactivity Problems DSM-oriented subscales (8.6% and 7.7%, respectively).

**Table 2.** Postnatal measures for participants of the current study.

|                                                | N          | M (±SD)      |
|------------------------------------------------|------------|--------------|
| Asthma control questionnaire                   | 55         | .833 (±1.07) |
| Postnatal EPDS                                 | 110        | 5.44 (±4.05) |
| 0–9 (Low risk)                                 | 93 (84.5%) |              |
| 10–12 (Medium risk)                            | 10 (9.1%)  |              |
| 13–30 (High risk)                              | 7 (6.4%)   |              |
|                                                | N          | (%)          |
| Mental health diagnoses                        | 110        |              |
| Depression                                     | 6          | (5%)         |
| Anxiety                                        | 4          | (4%)         |
| Depression and anxiety                         | 6          | (5%)         |
| Bipolar disorder                               | 2          | (2%)         |
| Depression and Borderline Personality disorder | 2          | (2%)         |
| Depression, Bipolar disorder and anxiety       | 1          | (1%)         |
| PTSD and anxiety                               | 1          | (1%)         |
| Any mental health diagnosis                    | 22         | (20%)        |
| Medicated for mental health issue <sup>a</sup> | 16         | (15%)        |
| Mental health care <sup>b</sup>                |            |              |
| Currently in (N = 118)                         | 16         | (14%)        |
| Past (N = 114)                                 | 54         | (47%)        |
| Alcohol use                                    | 117        |              |
| Rarely/never                                   | 81         | (69%)        |
| Once a month                                   | 19         | (16%)        |
| 1–2 days/week or more                          | 17         | (15%)        |
| Illicit drug use                               | 115        |              |
| Never                                          | 68         | (59%)        |
| Past use                                       | 43         | (37%)        |
| Current use <sup>c</sup>                       | 4          | (4%)         |

Abbreviations: N = sample size; M = sample mean; SD = sample standard deviation; EPDS = Edinburgh Postnatal Depression Scale; % = percent; PTSD = Post-traumatic Stress Disorder.

<sup>a</sup>Included any reported psychotropic medication used for the purposes of treating a mental illness/mood disorder. Two participants were taking medication for a mental health issue but did not disclose a diagnosis.

<sup>b</sup>Refers to self-reported visits to a psychologist or Counselor for psychotherapy, and does not necessarily reflect a diagnosis of a mental health disorder.

<sup>c</sup>Painkillers were reported for current drug use.

### Mental health and asthma results

Postnatal ACQ scores did not significantly correlate with prenatal or postnatal depression scores from the EPDS ( $r = .229$ ,  $p = .14$ , FDR-corrected  $p = 1.07$ ,  $r = .294$ ,  $p = .02$ , FDR-corrected  $p = .38$ ). Table 3 also shows the bivariate correlation coefficients between postnatal ACQ scores and ASR-based total scores of mental health. Postnatal asthma control was moderately correlated with many ASR DSM-5 oriented scales, syndrome scales, and problem scales. However, after FDR correction for multiple comparisons, nine scales remained statistically significant. Specifically, as shown in Table 3, poorer asthma control was more strongly associated with higher level of Somatic Problems and Antisocial Personality Problems on DSM-5 oriented scales, higher scores on the Withdrawn, Somatic complaints, Aggressive behavior and Intrusive Syndrome scales, and more Internalizing, Externalizing and Total Problems. The Antisocial Personality scale and Internalizing,

Externalizing and Total Problems scales may receive contributions from similar ASR items and therefore share variance. Prenatal spirometry or treatment adherence did not correlate with either prenatal or postnatal EPDS or any ASR measures ( $p = .24$  to  $p = 1.32$  FDR corrected). We calculated odds ratios to examine the incidence of poor mental health in asthmatic women during the postnatal period, as compared to normative healthy women. There was some indication that asthma raises the odds of having poorer postnatal mental health, particularly experiencing aggressive behavior (OR 1.26, 95% CI: 0.35–4.60) and attention deficit/hyperactivity problems (OR 1.70, 95% CI: 0.52–6.78). However, while these odd ratios are highly clinically significant, they were not statistically significant. No significant differences were found between prenatal or postnatal depression scores, or DSM-oriented or Syndrome scale scores between participants who used ICS and those that did not.

We found significant positive correlations between prenatal and postnatal EPDS scores ( $r = .458$ , FDR-corrected  $p < .01$ ). Additionally, modest, positive correlations were found between prenatal EPDS scores and total scores from the anxious depressed ASR scale ( $r = .557$ ,  $p < .01$  FDR), as well as the DSM-oriented depressive problems scale ( $r = .471$ ,  $p < .01$  FDR) and the anxiety problems scale ( $r = .462$ ,  $p < .01$  FDR). Strong correlations were found between postnatal EPDS scores and the anxious depressed scale ( $r = .657$ ,  $p < .01$  FDR), depressive problems ( $r = .662$ ,  $p < .01$  FDR), and anxiety problems ( $r = .495$ ,  $p < .01$  FDR) scales of the ASR.

### GINA severity and control results

One-hundred and nineteen women were classified as having mild, moderate, or severe prenatal asthma (Table 1). The majority of women had mild asthma (68.1%), while approximately half had uncontrolled asthma (50.4%) at their baseline pregnancy assessment. Univariate ANOVA analyses indicated that asthma severity status did not significantly influence prenatal or postnatal depression scores, or total scores on the DSM-5 oriented or syndrome scales of the ASR ( $p = .72$  to  $p = 1.69$  FDR corrected). Regression analyses revealed that psychological distress did not account for any variance in asthma severity and control groupings. Likewise, results from Chi-Square analyses indicated no differences in asthma severity or asthma control regardless of depression risk level either prenatally (severity:  $\chi^2(4, N = 101) = 2.4$ ,  $p = .664$ ; control:  $\chi^2(4, N = 101) = 8.6$ ,  $p = .073$ ) or

**Table 3.** Postnatal ASEBA subscale percentiles for participants, odds ratios and the bivariate correlation between ASEBA subscale total scores and postnatal asthma control questionnaire mean score.

| Subscale                                 | Borderline (93rd–97th percentile) <i>n</i> (%) | Odds ratio | Clinical (97th– 100th percentile) <i>n</i> (%) | Odds ratio | Correlation with postnatal asthma control |                |                              |
|------------------------------------------|------------------------------------------------|------------|------------------------------------------------|------------|-------------------------------------------|----------------|------------------------------|
|                                          |                                                |            |                                                |            | <i>R</i> <sup>a</sup>                     | <i>p</i> value | FDR-corrected <i>p</i> value |
| DSM-oriented subscales                   |                                                |            |                                                |            |                                           |                |                              |
| Depressive problems                      | 2 (1.9%)                                       | 0.41       | 2 (1.9%)                                       | 0.54       | .201                                      | .146           | .166                         |
| Anxiety problems                         | 3 (2.9%)                                       | 0.61       | 3 (2.9%)                                       | 0.83       | .075                                      | .589           | .589                         |
| Somatic problems                         | 4 (3.8%)                                       | 0.83       | 2 (1.9%)                                       | 0.54       | .461*                                     | <.001          | .009                         |
| Avoidant personality problems            | 5 (4.8%)                                       | 1.04       | 4 (3.8%)                                       | 1.12       | .272                                      | .047           | .073                         |
| Attention Deficit Hyperactivity problems | 2 (1.9%)                                       | 0.41       | 6 (5.8%)                                       | 1.70       | .282                                      | .039           | .066                         |
| Antisocial Personality                   | 1 (1.0%)                                       | 0.20       | 2 (1.9%)                                       | 0.54       | .506**                                    | <.001          | .006                         |
| Syndrome scales                          |                                                |            |                                                |            |                                           |                |                              |
| Anxious/Depressed                        | 4 (3.9%)                                       | 0.83       | 1 (1%)                                         | 0.27       | .164                                      | .235           | .250                         |
| Withdrawn                                | 2 (1.9%)                                       | 0.41       | 3 (2.9%)                                       | 0.83       | .490**                                    | <.001          | .004                         |
| Somatic complaints                       | 3 (2.9%)                                       | 0.61       | 3 (2.9%)                                       | 0.83       | .393**                                    | .003           | .009                         |
| Thought problems                         | 2 (1.9%)                                       | 0.41       | 4 (3.8%)                                       | 1.12       | .230                                      | .094           | .114                         |
| Attention problems                       | 4 (3.9%)                                       | 0.83       | 2 (1.9%)                                       | 0.54       | .271                                      | .047           | .067                         |
| Aggressive behavior                      | 6 (5.7%)                                       | 1.26       | 4 (3.8%)                                       | 1.12       | .407**                                    | .002           | .007                         |
| Rule-breaking behavior                   | 1 (1.0%)                                       | 0.20       | 0                                              |            | .232                                      | .092           | .120                         |
| Intrusive                                | 0                                              |            | 2 (1.9%)                                       | 0.54       | .389*                                     | .004           | .010                         |
| Internalizing problems                   | 1 (1%)                                         | 0.20       | 4 (3.8%)                                       | 1.12       | .324*                                     | .017           | .032                         |
| Externalizing problems                   | 1 (1%)                                         | 0.20       | 3 (2.9%)                                       | 0.83       | .430*                                     | .001           | .017                         |
| Total problems                           | 3 (2.9%)                                       | 0.61       | 4 (3.8%)                                       | 1.12       | .329*                                     | .015           | .032                         |

Abbreviations: DSM = Diagnostic and statistical manual of mental disorders; *N* = sample size; % = percent; *R* = Pearson correlation coefficient; FDR = False discovery rate.

\**p* < .05.

\*\**p* < .01.

<sup>a</sup>*R* values are bolded if significant after FDR correction.

No odds ratios were statistically significant.

postnatally (severity:  $\chi^2(4, N=91) = 4.7, p = .326$ ; control:  $\chi^2(4, N=91) = 1.8, p = .766$ ). Chi-squared analyses showed no significant differences in the proportion of asthma severity ( $\chi^2(2, N=109) = 0.248, p = .883$ ) or asthma control ( $\chi^2(2, N=109) = 1.364, p = .506$ ) between participants who reported being diagnosed with a mental health disorder and those who did not.

## Discussion

The present study aimed to characterize the presence and severity of psychopathology in the prenatal and postnatal period in asthmatic women, and investigate whether there is a relationship between psychopathology and severity or control of asthma during and after pregnancy. We found moderate correlations between poorer postnatal asthma control and elevated psychopathology at 6 weeks postpartum—and especially more somatic complaints, more externalizing problems and more withdrawn behaviors. Thus, women who reported poorer psychological well-being also reported poorer asthma control. In contrast, prenatal spirometry, or GINA-classified prenatal asthma severity and control were not associated with prenatal depression or postnatal psychological well-being.

These findings provide some evidence for a higher incidence of prenatal or postnatal psychopathology in

asthmatic women, when compared to non-asthmatic women. Twenty-two women (20.2%) reported having had a mental health diagnosis and 47% reported receiving mental health care in the past. Seventeen women (15.5%) scored medium to high levels of postnatal depression on the EPDS. These figures are within the range of recent estimates (45% (13), 28% (44), 6.1% (43) of prevalence of self-reported depression among women with asthma. However, despite elevated incidence of psychopathology in these women as compared to normative data from the ASR, odd ratios did not reach statistical significance.

It is likely that these findings underestimate the relationship between asthma and mental health concerns, as women from the BLT study who participated in the current study reported fewer mental illness symptoms than non-participants. Specifically, prenatal depression scores were significantly lower in participants than non-participants, and 31% of non-participants reported levels of prenatal depression that warranted further investigation. This is in line with findings from previous studies showing that women with asthma are at a somewhat elevated risk of anxiety and depression (e.g. (66)), including when pregnant (13,44). In conclusion, it is likely that if all women had participated in the follow up study, the relationship between asthma severity and control and psychological distress would have been stronger.

Previous studies report prevalence estimates of mental health among pregnant women with asthma, largely based on a self-reported clinical diagnosis. Here, we quantified the mental health diagnosis using self-report measures of adaptive and maladaptive behavior derived from the ASR scales, as well as the EPDS. Asthma control was significantly associated with internalizing problems, including withdrawn behaviors (e.g. loneliness and problems interacting with others) and somatic complaints (e.g. reports of aches, pains and experience of physical health), as well as externalizing problems, including antisocial personality features (e.g. arguing, rule-breaking and irresponsible behavior). These factors suggest a unique profile of psychopathology in asthmatic women, including avoidance and withdrawal from responsibilities during a stressful time in life, and/or a perceived lack of control over their life and asthma. Thus, a woman's subjective experience of asthma control in the early postpartum period appears to be strongly linked to level of postnatal psychopathology. While the incidence of poor mental health (specifically aggressive behavior and attention/deficit hyperactivity problems) in the sample did not reach statistical significance, the higher limit of the odds ratios were highly clinically significant. These findings need replication in a larger sample of asthmatic women to clarify the clinical profiles.

Interestingly, in contrast to earlier findings (e.g. (47)), there were no differences in psychopathology between women using ICS and those that were not, and there was no significant correlation between asthma symptoms and anxiety or depression levels. Perhaps the EPDS is not sensitive enough for characterizing the distinctive profile of psychopathology in asthmatic women, as simple anxiety and depression measures were not associated with either self-report or objective measures of asthma severity or control. An asthma-specific tool may be required.

Although self-report measures of psychopathology were correlated with self-reported asthma control, they did not correlate with objective measures of asthma severity, including prenatal spirometry. There are a number of possible reasons for this. First, it could be due to the temporal delay between recording the objective measures (prior to 23 weeks gestation) and the self-reported measures of psychopathology (6 weeks postpartum). Second, asthma severity (including spirometry) does not necessarily directly impact subjective experience of asthma severity (67). Some previous studies have found a relationship between asthma severity and mental health. For

instance, an early study found that in children, severe asthma was associated with more depressive symptoms (68), and another reported that more severe depressive symptoms are seen in adults with worse asthma, poorer asthma related quality of life and poorer physical health status (32). However, other studies have reported no association between objective measures of asthma severity and mental health (36,69,70). Yet, consistent with the present findings, studies using subjective measures (e.g. self-report measures like the ACQ as used here) have found significant associations between perceived asthma severity and depressive symptoms (71,72). Thirdly, the majority of women in this study had mild asthma (68.1%), and therefore their spirometry was typically within the normal range. This suggests that FEV<sub>1</sub> may be an insensitive measure in this population. Taken together, this suggests that the subjective perception of one's level of asthma control may more strongly impact or be impacted by one's mental health than the objective level of asthma severity. Mental health problems impact one's perception of how they are coping more generally, which may translate into how controlled they perceive their asthma to be, regardless of whether their asthma is well-controlled or not. How one perceives their asthma control in the early postnatal period may be more informative in determining their mental health postnatally. Last, it is also possible that this relationship could be due to measurement bias. Given that the source of the self-reported asthma control and the self-reported mental health is the same woman, it is possible that factors including her psychological health status and perceived life stress (e.g. (73)) may be impacting both measures.

Overall, the current findings, due to sample bias, are likely to underestimate the presence of mental health concerns in this population. However, the findings highlight the need to extensively examine the prevalence of psychiatric comorbidities in this vulnerable population of women. It is thought that the symptoms of depression, including low motivation, low energy, and apathy may reduce health seeking behaviors, the ability to self-manage and adhere to asthma medication, which may lead to more severe asthma symptoms and exacerbations during the pregnancy. It has been found that anxiety in asthmatic women can increase the likelihood of asthma exacerbations during pregnancy (46). Future research needs to consider asthma exacerbations in more detail. The effect of depression and anxiety treatment, either antidepressants or psychotherapy, on asthma outcomes

during pregnancy is yet to be studied, however, there is evidence to suggest that progressive muscle relaxation can improve lung parameters of asthma, anger and health related quality of life in asthmatic women during pregnancy (74).

## Conclusion

Mental health screening of women in the perinatal period is becoming more commonplace. This research points to a need for mental health screening with asthma-sensitive tools and specialized mental health interventions designed for asthmatic women during this time, as they may be at an elevated risk of psychopathology.

## Acknowledgements

We would like to thank the staff of the antenatal clinics at the John Hunter Hospital for assistance with patient recruitment and clinical assessment, and specifically Kelly Steel, Kathryn Jesson and Patricia Belinelo for assistance with assessment. We acknowledge Kathryn Jesson and Dr Ana Pereira de Siqueira for their role in smoothly organizing the transfer of participants from the BLT to the BLT-ID study. We thank all women who participated in the studies. We thank Annelies Robijn for assistance with data access.

## Financial Disclosure Statement

This project was a sub-study within a larger clinical randomized control trial. The sub-study, the Breathing for Life- Infant Development study, was conducted with financial assistance from the Priority Research Center GrowUpWell at The University of Newcastle.

The randomized control trial from which our participants were recruited, the Breathing for Life Trial, was supported by the National Health and Medical Research Council of Australia (\$1,114 750), grant no. G1400050. This grant was awarded to VM, alongside a large team. Trial registration number is ACTRN12613000202763. Further information can be found at <https://www.australianclinical-trials.gov.au/anzctr/trial/ACTRN12613000202763>.

CM, AW and OW were supported by a Research Training Program Stipend Scholarship Provided by the Australian Government. VM was supported by a Career Development Fellowship from the NHMRC (grant ID 1084816).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

## ORCID

Linda E. Campbell  <http://orcid.org/0000-0002-8872-9626>

Vanessa E. Murphy  <http://orcid.org/0000-0003-3282-1324>

Alison E. Lane  <https://orcid.org/0000-0003-0378-9716>

Peter G. Gibson  <http://orcid.org/0000-0001-5865-489X>

Joerg Mattes  <http://orcid.org/0000-0003-3729-5722>

Frini Karayanidis  <https://orcid.org/0000-0002-3317-9954>

## References

1. Mehta N, Chen K, Hardy E, Powrie R. Respiratory disease in pregnancy. *Best Pract Res Clin Obstet Gynaecol* 2015;29:598–611. doi:10.1016/j.bpobgyn.2015.04.005.
2. Clifton VL, Engel P, Smith R, Gibson P, Brinsmead M, Giles WB. Maternal and neonatal outcomes of pregnancies complicated by asthma in an Australian population. *Aust N Z J Obstet Gynaecol* 2009;49: 619–626. doi:10.1111/j.1479-828X.2009.01077.x.
3. Kwon HL, Belanger K, Bracken MB. Asthma prevalence among pregnant and childbearing-aged women in the United States: estimates from national health surveys. *Ann Epidemiol* 2003;13:317–324. doi:10.1016/S1047-2797(03)00008-5.
4. Rey E, Boulet L-P. Asthma in pregnancy. *BMJ* 2007; 334:582–585. doi:10.1136/bmj.39112.717674.BE.
5. Lundbäck B, Backman H, Lötval J, Rönmark E. Is asthma prevalence still increasing? *Expert Rev Respir Med* 2016;10:39–51. doi:10.1586/17476348.2016.1114417.
6. Murphy VE, Clifton VL, Gibson PG. Asthma exacerbations during pregnancy: incidence and association with adverse pregnancy outcomes. *Thorax* 2006;61: 169–176. doi:10.1136/thx.2005.049718.
7. Murphy V, Namazy J, Powell H, Schatz M, Chambers C, Attia J. A meta-analysis of adverse perinatal outcomes in women with asthma. *BJOG* 2011;118: 1314–1323. doi:10.1111/j.1471-0528.2011.03055.x.
8. Rejnö G, Lundholm C, Gong T, Larsson K, Saltvedt S, Almqvist C. Asthma during pregnancy in a population-based study-pregnancy complications and adverse perinatal outcomes. *PLoS One* 2014;9:e104755. doi: 10.1371/journal.pone.0104755.
9. Murphy VE, Jensen ME, Gibson PG, editors. Asthma during pregnancy: exacerbations, management, and health outcomes for mother and infant. *Semin Respir Crit Care Med* 2017;38(2):160–173.
10. Ali Z, Hansen A, Ulrik C. Exacerbations of asthma during pregnancy: impact on pregnancy complications and outcome. *J Obstet Gynaecol* 2016;36:455–461. doi:10.3109/01443615.2015.1065800.
11. Murphy VE, Wang G, Namazy JA, Powell H, Gibson PG, Chambers C. The risk of congenital malformations, perinatal mortality and neonatal hospitalisation among pregnant women with asthma: a systematic review and meta-analysis. *BJOG* 2013;120:812–822. doi:10.1111/1471-0528.12224.
12. Bonham CA, Patterson KC, Strek ME. Asthma outcomes and management during pregnancy. *Chest* 2018;153:515–527. doi:10.1016/j.chest.2017.08.029.
13. Grzeskowiak LE, Smith B, Roy A, Schubert KO, Baune BT, Dekker GA, Clifton VL. Impact of a history of maternal depression and anxiety on asthma control during pregnancy. *J Asthma* 2017;54:706–713. doi:10.1080/02770903.2016.1258080.

14. Ogbo FA, Eastwood J, Hendry A, Jalaludin B, Agho KE, Barnett B, Page A. Determinants of antenatal depression and postnatal depression in Australia. *BMC Psychiatry* 2018;18:49. doi:10.1186/s12888-018-1598-x.
15. Eastwood J, Ogbo FA, Hendry A, Noble J, Page A, Group E. The impact of antenatal depression on perinatal outcomes in Australian women. *PLoS One* 2017; 12:e0169907. doi:10.1371/journal.pone.0169907.
16. Leigh B, Milgrom J. Risk factors for antenatal depression, postnatal depression and parenting stress. *BMC Psychiatry* 2008;8:24.
17. Edwards B, Galletly C, Semmler-Booth T, Dekker G. Antenatal psychosocial risk factors and depression among women living in socioeconomically disadvantaged suburbs in Adelaide, South Australia. *Aust N Z J Psychiatry* 2008;42:45–50. doi:10.1080/00048670701732673.
18. Eastwood JG, Phung H, Barnett B. Postnatal depression and socio-demographic risk: factors associated with Edinburgh Depression Scale scores in a metropolitan area of New South Wales, Australia. *Aust N Z J Psychiatry* 2011;45:1040–1046. doi:10.3109/00048674.2011.619160.
19. Slade T, Johnston A, Oakley Browne MA, Andrews G, Whiteford H. 2007 National Survey of Mental Health and Wellbeing: methods and key findings. *Aust N Z J Psychiatry* 2009;43:594–605. doi:10.1080/00048670902970882.
20. Gaynes BN, Gavin N, Meltzer-Brody S, Lohr KN, Swinson T, Gartlehner G, Brody S, Miller WC. Perinatal depression: prevalence, screening accuracy, and screening outcomes. *Evid Rep Technol Assess* 2005;(119):1–8.
21. Howard LM, Molyneaux E, Dennis C-L, Rochat T, Stein A, Milgrom J. Non-psychotic mental disorders in the perinatal period. *Lancet* 2014;384:1775–1788. doi:10.1016/S0140-6736(14)61276-9.
22. Munk-Olsen T, Laursen TM, Pedersen CB, Mors O, Mortensen PB. New parents and mental disorders: a population-based register study. *JAMA* 2006;296: 2582. doi:10.1001/jama.296.21.2582.
23. Rahman A, Iqbal Z, Bunn J, Lovel H, Harrington R. Impact of maternal depression on infant nutritional status and illness: a cohort study. *Arch Gen Psychiatry* 2004;61:946–952. doi:10.1001/archpsyc.61.9.946.
24. Lovejoy MC, Graczyk PA, O'Hare E, Neuman G. Maternal depression and parenting behavior: A meta-analytic. *Rev Clin Psychol Rev* 2000;20:561–592. doi: 10.1016/S0272-7358(98)00100-7.
25. Malphurs JE, Raag T, Field T, Pickens J, Pelaez, Noguera M. Touch by intrusive and withdrawn mothers with depressive symptoms. *Early Dev Parenting* 1996;5:111–115. doi:10.1002/(SICI)1099-0917(199606)5:2<111::AID-EDP122>3.0.CO;2-#.
26. McLearn KT, Minkovitz CS, Strobino DM, Marks E, Hou W. Maternal depressive symptoms at 2 to 4 months post partum and early parenting practices. *Arch Pediatr Adolesc Med* 2006;160:279–284. doi: 10.1001/archpedi.160.3.279.
27. Beardslee WR, Versage EM, Gladstone TR. Children of affectively ill parents: a review of the past 10 years. *J Am Acad Child Adolesc Psychiatry* 1998;37: 1134–1141.
28. Giallo R, Bahreinian S, Brown S, Cooklin A, Kingston D, Kozyrskyj A. Maternal depressive symptoms across early childhood and asthma in school children: findings from a longitudinal Australian population based study. *PLoS One* 2015;10:e0121459. doi:10.1371/journal.pone.0121459.
29. Lu Z, Chen L, Xu S, Bao Q, Ma Y, Guo L. Allergic disorders and risk of depression: a systematic review and meta-analysis of 51 large-scale studies. *Ann Allergy Asthma Immunol* 2018;120:310–317. e2. doi: 10.1016/j.anai.2017.12.011.
30. Scott KM, Von Korff M, Ormel J, Zhang M-Y, Bruffaerts R, Alonso J, Kessler RC, Tachimori H, Karam E, Levinson D, et al. Mental disorders among adults with asthma: results from the World Mental Health Survey. *Gen Hosp Psychiatry* 2007;29:123–133. doi:10.1016/j.genhosppsy.2006.12.006.
31. Cluley S, Cochrane G. Psychological disorder in asthma is associated with poor control and poor adherence to inhaled steroids. *Res Med* 2001;95: 37–39. doi:10.1053/rmed.2000.0968.
32. Eisner MD, Katz PP, Lactao G, Iribarren C. Impact of depressive symptoms on adult asthma outcomes. *Ann Allergy Asthma Immunol* 2005;94:566–574. doi: 10.1016/S1081-1206(10)61135-0.
33. Di Marco F, Verga M, Santus P, Giovannelli F, Busatto P, Neri M, Girbino G, Bonini S, Centanni S. Close correlation between anxiety, depression, and asthma control. *Res Med* 2010;104:22–28. doi:10.1016/j.rmed.2009.08.005.
34. Lavoie KL, Cartier A, Labrecque M, Bacon SL, Lemi re C, Malo J-L, Lacoste G, Barone S, Verrier P, Ditto B. Are psychiatric disorders associated with worse asthma control and quality of life in asthma patients? *Res Med* 2005;99:1249–1257. doi:10.1016/j.rmed.2005.03.003.
35. Pilipenko N, Karekla M, Georgiou A, Feldman J. Impact of psychiatric illness upon asthma patients' health care utilization and illness control. Are all psychiatric comorbidities created equal? *Psychol Health Med* 2016;21:787–799. doi:10.1080/13548506.2015.1131995.
36. Chapman K. Impact of 'mild' asthma on health outcomes: findings of a systematic search of the literature. *Res Med* 2005;99:1350–1362. doi:10.1016/j.rmed.2005.03.020.
37. Barton C, Clarke D, Sulaiman N, Abramson M. Coping as a mediator of psychosocial impediments to optimal management and control of asthma. *Res Med* 2003;97:747–761.
38. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. *Arch Intern Med* 2000;160:2101–2107.
39. Lehrer P, Feldman J, Giardino N, Song H-S, Schmalin K. Psychological aspects of asthma. *J Consult Clin Psychol* 2002;70:691–711.

40. Foster SL, Seehus CR, Woolf CJ, Talbot S. Sense and immunity: context-dependent neuro-immune interplay. *Front Immunol* 2017;8:1463.
41. Thoren CT, Petermann F. Reviewing asthma and anxiety. *Res Med* 2000;94:409–415.
42. Walters P, Schofield P, Howard L, Ashworth M, Tylee A. The relationship between asthma and depression in primary care patients: a historical cohort and nested case control study. *PLoS One* 2011;6:e20750. doi:10.1371/journal.pone.0020750.
43. Blais L, Ahmed SIS, Beauchesne M-F, Forget A, Kettani F-Z, Lavoie KL. Risk of postpartum depression among women with asthma. *J Allergy Clin Immunol Pract* 2019;7(3):925–933.e2.
44. Zairina E, Abramson MJ, McDonald CF, Li J, Dharmasiri T, Stewart K, Walker SP, Paul E, George J. Telehealth to improve asthma control in pregnancy: a randomized controlled trial. *Respirology* 2016;21:867–874. doi:10.1111/resp.12773.
45. Tata LJ, Lewis SA, McKeever TM, Smith CJP, Doyle P, Smeeth L, West J, Hubbard RB. A comprehensive analysis of adverse obstetric and pediatric complications in women with asthma. *Am J Respir Crit Care Med* 2007;175:991–997. doi:10.1164/rccm.200611-1641OC.
46. Powell H, McCaffery K, Murphy VE, Hensley MJ, Clifton VL, Giles W, Gibson PG. Psychosocial variables are related to future exacerbation risk and perinatal outcomes in pregnant women with asthma. *J Asthma* 2013;50:383–389. doi:10.3109/02770903.2012.757777.
47. Price DB, Trudo F, Voorham J, Xu X, Kerkhof M, Ling Zhi Jie J, Tran TN. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. *J Asthma Allergy* 2018;11:193–204. doi:10.2147/JAA.S176026.
48. Kullovatz A, Kannies F, Dahme B, Magnussen H, Ritz T. Association of depression and anxiety with health care use and quality of life in asthma patients. *Respir Med* 2007;101:638–644. doi:10.1016/j.rmed.2006.06.002.
49. Bonala SB, Pina D, Silverman BA, Amara S, Bassett CW, Schneider AT. Asthma severity, psychiatric morbidity, and quality of life: correlation with inhaled corticosteroid dose. *J Asthma* 2003;40:691–699.
50. Murphy VE, Jensen ME, Mattes J, Hensley MJ, Giles WB, Peek MJ, Bisits A, Callaway LK, McCaffery K, Barrett HL, et al. The Breathing for Life Trial: a randomised controlled trial of fractional exhaled nitric oxide (FENO)-based management of asthma during pregnancy and its impact on perinatal outcomes and infant and childhood respiratory health. *BMC Pregnancy Childbirth* 2016;16:111.
51. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, Enright PL, Hankinson JL, Ip MS, Zheng J, et al. Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. *Eur Respiratory Soc* 2012;40:1324–1343.
52. Murphy VE, Gibson PG, Talbot PI, Kessell C, Clifton VL. Asthma self-management skills and the use of asthma education during pregnancy. *Eur Respiratory J* 2005;26:435–441. doi:10.1183/09031936.05.00135604.
53. Juniper E, O' byrne P, Guyatt G, Ferrie P, King D. Development and validation of a questionnaire to measure asthma control. *Eur Respir J* 1999;14:902–907. doi:10.1034/j.1399-3003.1999.14d29.x.
54. Juniper EF, Bousquet J, Abetz L, Bateman ED, Committee G. Identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire. *Respir Med* 2006;100:616–621. doi:10.1016/j.rmed.2005.08.012.
55. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma. Available from: <https://ginasthma.org/wp-content/uploads/2018/04/wms-GINA-2018-report-V1.3-002.pdf> [last accessed 07 May 2018].
56. Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. *Br J Psychiatry* 1987;150:782–786. doi:10.1192/bjp.150.6.782.
57. Achenbach TM, Rescorla L. Manual for the ASEBA adult forms & profiles. Burlington, VT: University of Vermont, Research Center for Children, Youth; 2003.
58. Bergant AM, Nguyen T, Heim K, Ulmer H, Dapunt O. Deutschsprachige Fassung und Validierung der »Edinburgh postnatal depression scale«. *DMW* 2008;123:35–40. doi:10.1055/s-2007-1023895.
59. Kernot J, Olds T, Lewis LK, Maher C. Test-retest reliability of the English version of the Edinburgh Postnatal Depression Scale. *Arch Women's Mental Health* 2015;18:255–257. doi:10.1007/s00737-014-0461-4.
60. Teissèdre F, Chabrol H. Detecting women at risk for postnatal depression using the Edinburgh postnatal depression scale at 2 to 3 days postpartum. *Can J Psychiatry* 2004;49:51–54. doi:10.1177/070674370404900108.
61. Cox JL, Holden J. Perinatal psychiatry: use and misuse of the Edinburgh Postnatal Depression Scale. London: Gaskell; 1994.
62. Bergink V, Kooistra L, Lambregtse-van den Berg MP, Wijnen H, Bunevicius R, van Baar A, Pop V. Validation of the Edinburgh depression scale during pregnancy. *J Psychosom Res* 2011;70:385–389. doi:10.1016/j.jpsychores.2010.07.008.
63. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5®). Arlington, VA: American Psychiatric Publishing; 2013.
64. Agresti A. An introduction to categorical data analysis. Hoboken, NJ: Wiley; 2018.
65. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J R Stat Soc Ser B (Methodological)* 1995; 57:289–300. doi:10.1111/j.2517-6161.1995.tb02031.x.
66. Scott KM, Bruffaerts R, Tsang A, Ormel J, Alonso J, Angermeyer MC, Benjet C, Bromet E, de Girolamo G, de Graaf R, et al. Depression-anxiety relationships with chronic physical conditions: results from the World Mental Health Surveys. *J Affect Disord* 2007;103:113–120. doi:10.1016/j.jad.2007.01.015.

67. Opolski M, Wilson I. Asthma and depression: a pragmatic review of the literature and recommendations for future research. *Clin Pract Epidemiol Ment Health* 2005;1:18. doi:[10.1186/1745-0179-1-18](https://doi.org/10.1186/1745-0179-1-18).
68. Mrazek D. Psychiatric complications of pediatric asthma. *Ann Allergy* 1992;69:285–290.
69. Afari N, Schmalting KB, Barnhart S, Buchwald D. Psychiatric comorbidity and functional status in adult patients with asthma. *J Clin Psychol Med Settings* 2001;8:245–252. doi:[10.1023/A:1011912712262](https://doi.org/10.1023/A:1011912712262).
70. Janson C, Björnsson E, Hetta J, Boman G. Anxiety and depression in relation to respiratory symptoms and asthma. *Am J Respir Crit Care Med* 1994;149:930–934. doi:[10.1164/ajrccm.149.4.8143058](https://doi.org/10.1164/ajrccm.149.4.8143058).
71. Janson-Bjerklie S, Ferketich S, Benner P, Becker G. Clinical markers of asthma severity and risk: importance of subjective as well as objective factors. *Heart Lung* 1992;21:265–272.
72. Kovács M, Stauder A, Szedmák S. Severity of allergic complaints: the importance of depressed mood. *J Psychosom Res* 2003;54:549–557.
73. Garrity TF, Somes GW, Marx MB. Factors influencing self-assessment of health. *Soc Sci Med* 1978;12:77–81. doi:[10.1016/0271-7123\(78\)90032-9](https://doi.org/10.1016/0271-7123(78)90032-9).
74. Nickel C, Lahmann C, Muehlbacher M, Pedrosa Gil F, Kaplan P, Buschmann W, Tritt K, Kettler C, Bachler E, Egger C, et al. Pregnant women with bronchial asthma benefit from progressive muscle relaxation: a randomized, prospective, controlled trial. *Psychother Psychosom* 2006;75:237–243. doi:[10.1159/000092894](https://doi.org/10.1159/000092894).